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The U.S. National Toxicology Program
(NTP) is currently the main international
source of rodent bioassay data, having
reported on the carcinogenic activities of
about 500 chemicals over the past 25 years
(1). However, the disparity between the large
number of chemicals considered worthy of
evaluation for rodent carcinogenicity and the
limited resources available for this task has
led to consideration of a range of alternatives
to the classical two-species rodent carcino-
genicity bioassay protocol. Such alternatives
extend from a variety of predictive techniques
based on the chemical structure and genetic
toxicity of chemicals (2) to the use of acceler-
ated carcinogenicity bioassays based on the
use of genetically modiﬁed rodents (3).
A serious complication in attempting to
replace the standard bioassay is that different
chemicals produce different tumors in differ-
ent tissues and species of rodents, and it is
unclear which of these tumor proﬁles deﬁne
those carcinogens most likely to pose a com-
mensurate hazard to humans. At the sim-
plest level this is captured by the dichotomy
between genotoxic and nongenotoxic rodent
carcinogens. Such uncertainties become
important when attempting to validate
accelerated alternatives to the standard two-
species rodent assay. For example, it is cur-
rently unclear whether any of the proposed
alternatives should be required to predict the
carcinogenicity of presumed nongenotoxic
rodent carcinogens such as sodium saccharin
and limonene, or whether their value should
be judged in relation to their sensitivity to
genotoxic (mutagenic) carcinogens such as
dimethylnitrosamine, benzo[a]pyrene, and
aﬂatoxin B1. Pending resolution of this cen-
tral question, there remains the regulatory
need to identify, as efficiently as possible,
both genotoxic and presumed nongenotoxic
carcinogens to which humans may be
exposed.
Methods probably already exist that can
be used to anticipate, with an acceptable level
of certainty, those rodent carcinogens that
can noncontroversially be classiﬁed as geno-
toxic. These carcinogens are usually active in
both rats and mice, and they are generally
carcinogenic to more than one tissue.
Consistent with these activities, they are usu-
ally overtly active in short-term in vitro and
in vivo genetic toxicity assays. Designing
alternative techniques for the prediction and
recognition of such carcinogens will therefore
be relatively easy, the only possible complica-
tion being the large number of candidate
assays available for use.
The more difﬁcult challenge is to devise
reliable assays for the prediction and recogni-
tion of nongenotoxic rodent carcinogens
(4,5). Apart from the difficulty of deciding
the relevance of such rodent carcinogens to
humans, there is the possibility that the
species, sex, and tissue speciﬁcity of such car-
cinogens will be uniquely associated with
chemically induced changes that occur only
within the tissues subject to carcinogenesis.
Approaches to this problem have been made
by Tennant and colleagues (6,7), who pro-
posed that a battery of different transgenic
mice may be used to predict genotoxic and
nongenotoxic carcinogens, and by Yamasaki
(8), who has assessed the ability of the Syrian
hamster cell transformation assay to predict
all classes of rodent carcinogen in vitro. We
designed the present study to evaluate the
proposition that, for example, the unique car-
cinogenicity of ethylene thiourea to the rat
thyroid gland and the unique carcinogenicity
of limonene to the male rat kidney are associ-
ated with acute and subacute biologic changes
occurring uniquely in those species and tissues
subject to carcinogenesis by these agents (9). 
We selected nine NTP carcinogens for
study (Table 1); their carcinogenic status,
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Articles
We studied nine presumed nongenotoxic rodent carcinogens, as defined by the U.S. National
Toxicology Program (NTP), to determine their ability to induce acute or subacute biochemical
and tissue changes that may act as useful predictors of nongenotoxic rodent carcinogenesis. The
chemicals selected included six liver carcinogens (two of which are peroxisome proliferators),
three thyroid gland carcinogens, and four kidney carcinogens. We administered the chemicals
(diethylhexyl phthalate, cinnamyl anthranilate, chlorendic acid, 1,4-dichlorobenzene, monuron,
ethylene thiourea, diethyl thiourea, trimethyl thiourea, and d-limonene) to the same strains of
mice and rats used in the original NTP bioassays (nine chemicals to rats and seven to mice).
Selected tissues (liver, thyroid gland, and kidney) were collected from groups of animals at 7, 28,
and 90 days for evaluation. Tissue changes selected for study were monitored for all of the test
groups, irrespective of the speciﬁcity of the carcinogenic responses observed in those tissues. This
allowed us to assess both the carcinogen specificity and the carcinogen sensitivity of the events
being monitored. We studied relative weight, cell labeling indices, and pathologic changes such as
hypertrophy in all tissues; a range of cytochrome P450 enzymes and palmitoyl coenzyme A oxi-
dase in the liver; changes in the levels of plasma total triiodothyronine, total thyroxine, and thy-
roid-stimulating hormone (TSH) as markers of thyroid gland function; and hyaline droplet
formation, tubular basophilia, and the formation of granular casts in the kidney. There were no
single measurements that alerted specifically to the carcinogenicity of the agents to the rodent
liver, thyroid gland, or kidney. However, in the majority of cases, the chemical induction of can-
cer in a tissue was preceded by a range of biochemical/morphologic changes, most of which were
moderately specific for a carcinogenic outcome, and some of which were highly specific for it
(e.g., increases in TSH in the thyroid gland and increases in relative liver weight in the mouse).
The only measurements that failed to correlate usefully with carcinogenicity were the induction
of liver enzymes (with the exception of the enzymes associated with peroxisome proliferation).
Most of the useful markers were evident at the early times studied (7 days and 28 days), but no
overall best time for the measurement of all markers was identiﬁed. The judicious choice of mark-
ers and evaluation times can aid the detection of potential nongenotoxic rodent carcinogens. Key
words: kidney, liver, nongenotoxic carcinogenesis, thyroid. Environ Health Perspect 110:363–375
(2002). [Online 7 March 2002] 
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Table 1. Carcinogenicity data for the nine compounds used in these studies. 
Abbreviations: K, kidney (tubular cell); L, liver; P, pancreas (acinar cell); PTG, pituitary gland; TBA, tumor-bearing animals; TG, thyroid gland (follicular cell). Tumor codes: no symbol, car-
cinomas; *carcinomas + adenomas; **adenomas only, ***hyperplasia. Carcinogenic status as described in the NTP reports: CE, clear evidence for carcinogenicity; NE, no evidence for
carcinogenicity. Carcinogenic status as described by Haseman et al. (44): N,negative for carcinogenicity; P,positive for carcinogenicity. Tumor data were summarized from the NTP
Technical Reports cited; only the tumor data that led to the classiﬁcation of the compound as carcinogenic are displayed. 
aMales and females received identical doses unless indicated otherwise. bDose levels for feeding studies are grams compound per 100 grams diet. cDose levels for gavage studies are
milligrams compound per kilogram body weight per day. including an estimate of carcinogenicity at the
lower of the two dose levels evaluated by the
NTP, is summarized in Table 2. The chemi-
cals selected include six liver carcinogens (two
of which are peroxisome proliferators), three
thyroid gland carcinogens, and four kidney
carcinogens (including limonene, which is the
most well-documented example of α2u-glob-
ulin-associated renal carcinogenesis in the
male rat). The chemical structures of these
agents, their general absence of genetic toxic-
ity as reported in the appropriate NTP bioas-
say report, and the tissue and species
speciﬁcity of their carcinogenic activities are
all consistent with them being regarded as
presumptive nongenotoxic carcinogens.
Further, for the major tissues subject to car-
cinogenesis (liver, thyroid gland, and kid-
ney), other investigators have described data
consistent with the susceptibility of these tis-
sues to nongenotoxic carcinogenesis (7). 
We administered the chemicals at the
same dose levels to the same strains of mice
and rats used in the original NTP bioassays
(10–18) (nine chemicals to rats, seven to
mice). We collected tissues from groups of
animals at 7, 28, and 90 days for evaluation
of target tissues for those changes that have
been proposed to represent an aspect of the
carcinogenic process in these tissues, and
consequently, to be considered as predictive
of nongenotoxic carcinogenesis. One unique
aspect of our study is that we monitored the
tissue changes selected for study for all of the
test groups, irrespective of the species and
sex speciﬁcity of the carcinogenic responses
observed in that tissue. This allowed unique
insights into both the carcinogen speciﬁcity
and the carcinogen sensitivity of the marker
events being monitored.
The results generated by our investiga-
tions are extensive, and we believe that it is
more helpful to present in detail only some of
the experimental data. Our approach was to
consider data in the context of addressing spe-
ciﬁc questions related to utility or speciﬁc tis-
sue responses as predictors of nongenotoxic
rodent carcinogenesis (Table 3). We assumed
from the outset that for a biologic change in a
tissue to be considered useful for the predic-
tion of nongenotoxic carcinogenesis in that
tissue, it would have to be clear, unequivocal,
and speciﬁc to the carcinogens. To that end,
the test data have not been analyzed for statis-
tical signiﬁcance. In practice, that means the
“Discussion” section of this paper is con-
cerned only with self-evident results. Clearly,
that enabling decision may have obscured
subtle tissue changes of possible signiﬁcance
to the carcinogenic process, but such changes
were not considered relevant to the stated
aims of the study. To compensate for this
decision, the complete database is available
from the authors (compact disc) to enable
other interested investigators to scrutinize and
assess statistically the results.
Materials and Methods
Chemicals
Monuron (MON, 99% pure), ethylene
thiourea (2-imidazolidine ethione; ETU,
98% pure), diethyl thiourea (DETU, 98%
pure), R(+)-limonene (d-limonene; LIM,
97% pure), diethylhexyl phthalate (dioctyl
phthalate; DEHP, 99% pure), and 1,4-
dichlorobenzene (DCB, 99% pure) were
obtained from Aldrich Chemical Co.,
(Gillingham, Dorset, UK). Chlorendic acid
as the anhydride (CEA, > 99 % pure) was
obtained from Aldrich Chemical Co. and
was hydrolyzed before use. Trimethyl
thiourea (TMTU, > 98% pure) was obtained
from Tokyo Chemical Industries Inc. via
Fluochem Ltd. (Glossop, Derbyshire, UK).
Cinnamyl anthranilate, (CINN, > 99% pure)
was synthesized by Lancaster Synthesis
(Morecambe, Lancashire, UK).
Animals
Fischer 344 rats (6–7 weeks old on arrival)
were obtained from Harlan UK (Bicester,
Oxfordshire, UK) and were allowed approxi-
mately 2 weeks acclimatization. B6C3F1 mice
(4–5 weeks old on arrival) were also obtained
from Harlan UK and were allowed approxi-
mately 4 weeks acclimatization. We per-
formed animal studies in accordance with the
UK “Animals (Scientific Procedures) Act.”
Animal care and procedures were carried out
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Table 2. Qualitative conclusions of the carcinogenicity of the nine test agents.
Liver Thyroid Kidney
Rat Mouse Rat Mouse Rat Mouse
Test agent Male Female Male Female Male Female Male Female Male Female Male Female
(reference) L H L H L H L H L H L H L H L H L H L H L H L H
DEHP (13)+ * + + + ++ +  + –– –  – –  – –  – –  – –  – – – – –
CINN (12)– – – – + + +  + – – –  – –  – –  – –  + –  – – – – –
CEA (14)+ + + + + + –  – – – –  – –  – –  – –  – –  – – – – –
DCB (15)– – – – + * +–  + – ––  ––  – –  –+ *  +–  – – –– –
MON (16)+ * + –– –– –  – –– –  – –  – –  – + *  + –  – –– ––
ETU (18)– – – – + + +  + + ++  + –  ++ *  +–  – –  –– – – –
DETU (10)– – – – – – –  – – * + +  + –  ––  – –  ––  – – –– –
TMTU (11)– – – – N S N S – – – *  +N S N S –  – –  – N S N S
LIM (17)– – – – N S N S – – –  – N SN S +  + –  – N SN S
Abbreviations: H, high dose; L, low dose; NS, not studied. Conclusions were based on the NTP bioassays; the low-dose classiﬁcations were provided by J. Haseman of the NTP. 
*Haseman prefaced his conclusion with the word “probably.”
Table 3. Questions about predicting nongenotoxic carcinogenesis in the rodent addressed in the present
study.
Liver markers To what extent are the following events associated speciﬁcally with liver
carcinogenesis in the rat and mouse?
Liver weight increases
Liver cell hypertrophy and hyperplasia
Increases in liver cell labeling index
PCoA oxidase induction
Total cytochrome P450 induction
Induction of CYP 1A1, 2B1/2, 3A1, and 4A1
Thyroid gland markers To what extent are the following events associated speciﬁcally with thyroid
gland carcinogenesis in the rat and mouse? 
Thyroid gland weight increases 
Follicular cell hypertrophy and hyperplasia 
Increases in thyroid cell labeling index
Changes in total plasma T3 and T4 levels 
Compensatory changes to plasma TSH levels
Kidney markers To what extent are the following events associated speciﬁcally with kidney
carcinogenesis in the male rat?
Kidney weight changes
Kidney pathology
Increases in kidney cell labeling index
Time of measurement What is the optimum time for measuring those changes that appear to be
associated with carcinogenesis?according to in-house standards; all animals
were housed in wire mesh cages. In the origi-
nal NTP studies, animals were housed in
solid cages with bedding; although housing
animals in wire cages may remove contami-
nants from the animals’ environment, we
considered the caging difference to be of
only minor significance. The temperature
was controlled at 22° ± 3°C, humidity was
controlled at 30–70%, and a 12hr/12hr
light/dark cycle was maintained. Animals
received PCD diet (Special Diet Services
Ltd, Witham, Essex, UK), either untreated
or combined with compound. Diet and
water were available ad libitum.
Studies
Rats and mice were exposed to chemicals for
7, 28, or 90 days either in the diet (DEHP,
CINN, CEA, MON, ETU, DETU, and
TMTU) or by oral gavage (DCB and LIM).
TMTU and LIM were not administered to
mice. DEHP, CINN, CEA, MON, ETU,
DETU, and TMTU were also administered
for 365 days as satellite studies designed to
study the time course of the changes in more
detail. The results of those studies are not
described here, except for the tumor inci-
dences that were pertinent to the present
results. Chemicals were homogeneously
incorporated into the diet. Dietary analysis,
carried out using methods specified in the
NTP reports (10–18), conﬁrmed that homo-
geneity and the target concentrations had
been achieved. Dietary administration was
continuous from the start of the studies until
termination. We monitored food consump-
tion weekly. Oral gavage was carried out
daily, 5 days/week, except for the ﬁnal 7 days
of the studies (when minipumps were
implanted) when oral gavage was carried out
on all 7 days. Animals were terminated 24 hr
after the ﬁnal dose.
For determination of DNA synthesis
(labeling indices), we implanted animals with
osmotic minipumps (Rats: Altzet 2ML1;
mice; Altzet 2001; both from Charles River
UK Ltd, Margate, Kent, UK) containing
bromodeoxyuridine (BRDU; 15 mg/mL in
phosphate-buffered saline, pH 7.4) 7 days
before termination. Animals were anes-
thetized with halothane, minipumps were
inserted subcutaneously on the ﬂank, and the
wounds were closed with surgical clips or
sutures.
Animals were killed by exposure to car-
bon dioxide, and blood was collected by car-
diac puncture. Organs (liver, kidney, and
thyroid gland) were removed and weighed,
and sections were taken. The tissues were
then processed by standard histologic proce-
dures to paraffin blocks. Sections were cut
and stained with hematoxylin and eosin
(H&E) for histopathologic examination by
standard procedures. Thyroid glands (rats
only) were weighed after fixation in formol
saline and subsequent separation from the
trachea. Thyroid glands in mice were too
small to be accurately dissected and weighed.
Additional sections were taken for determi-
nation of cell labeling indices (percentages of
cells in S phase) by BRDU incorporation
using the method of Soames et al. (19). 
We homogenized the remaining hepatic
tissue with a teﬂon-glass homogenizer in SET
buffer (0.25 M sucrose, 5.4 mM EDTA 20
mM Tris-HCl, pH7.4) and prepared peroxi-
somal fractions (20). Microsomal fractions
were prepared by centrifugation of the post-
peroxisomal supernatant at 105,000 g for 1
hr. The pellets were resuspended in 1.15%
KCl containing 20mM Tris HCl, pH7.4,
and centrifuged again at 105,000 g for 1 hr.
The subcellular fractions were resuspended in
SET and stored at –70°C.
Assays
Liver. We used the method of Omura and
Sato (21) to determine the cytochrome
P450 content of liver microsomes. We
determined isoenzyme profiles on microso-
mal fractions using SDS-gel electrophoresis
and Western blotting according to the gen-
eral method of Bars et al. (22), with chemi-
luminescence detection using the Western
Light kit (Tropix, Bedford, MA, USA).
Antibodies to P450s 1A1, 2B1/2, and 3A1
were supplied by Oxygene (Dallas, TX,
USA), and antibodies to P4504A1 were a
gift from David Bell (University of
Nottingham, England). Positive controls
used for the isoenzyme proﬁles were micro-
somes from animals treated intraperitoneally
for 4 days with standard P450 inducing
agents (23): β-naphthoﬂavone (100 mg/kg),
phenobarbitone (80 mg/kg), dexamethasone
(50 mg/kg), and methylclofenapate (25
mg/kg). We analyzed Western blots by eye
and scored increases in P450 isozyme pro-
ﬁles relative to the negative and positive con-
trols as either no changes in any animals
(relative to negative controls), one or more
animals showing mild increases, or one or
more animals showing moderate or marked
increases (marked increases were categorized
as being of similar intensity to the positive
control). Generally, there was little variation
in response between animals. Palmitoyl
coenzyme A oxidase activity (PCoA) was
determined on peroxisomal fractions (24)
and protein was determined using the
method of Lowry et al. (25).
Thyroid. Plasma was prepared by cen-
trifugation of whole blood. We determined
plasma thyroid-stimulating hormone (TSH),
total thyroxine (T4), and triiodothyronine
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Table 4. Parameters measured as potential predictors of nongenotoxic carcinogenesis and criteria used
to deﬁne a biologically signiﬁcant change.
Resultsb
Parameter No.a Clearly positive Equivocal result Negative result
Liver
Relative liver weightc 10 ≥ 120% 110–119% < 110%
Labeling indexc 10 ≥ 200% 150–199% <  150%
Liver hypertrophyd 10 ≥ 50% moderate–marked ≤ 50% moderate–marked Minimal/none
PCoA 5 ≥ 250% 200–249% <  200%
oxidase inductionc
Total P450 inductione 5 ≥ 120% 115–119% <  115%
P450 1A1 inductione 3 Moderate–marked Mild No change
P450 2B1/2 inductione 3 Moderate–marked Mild No change
P450 3A1 inductione 3 Moderate–marked Mild No change
P450 4A1 inductione 3 Moderate–marked Mild No change
Thyroid
Relative thyroid weightc 10 ≥ 125% 115–124% < 115%
Labeling indexc 10 ≥ 200% 150–199% <  150%
Hypertrophyd 10 ≥ 50% moderate–marked ≤ 50% moderate–marked Minimal/none
Hyperplasiad 10 ≥ 50% moderate–marked ≤ 50% moderate–marked Minimal/none
Plasma total T3
c 5 ≤ 70% 71–80% > 80%
Plasma T4
c 5 ≤ 70% 71–80% > 80%
Plasma TSHc 5 ≥ 200% 150–199% <  150%
Kidney
Relative thyroid weightc 10 ≥ 110% 105–109% < 105%
Labeling indexc 10 ≥ 200% 150–199% <  150%
Hyaline droplet formation 10 ≥ 50% moderate–marked ≤ 50% moderate–marked Minimal/none
Tubular basophiliad 10 ≥ 50% moderate–marked ≤ 50% moderate–marked Minimal/none
Granular cast formationd 10 ≥ 50% moderate–marked ≤ 50% moderate–marked Minimal/none
The criteria are arbitary and were based on the data obtained with the parameters, our experience, and data from the
literature. 
aNumber of animals analyzed per group. bGroup mean results. cChanges expressed as percent of control values.
dChanges were assessed by histopathologic examination. Percentages indicate numbers of animals showing effects of
this severity, compared to the incidence in control animals; in all cases only minimal or no effects were seen in control
animals. eOne or more animals showed the change indicated relative to the control group (marked increases were cate-
gorized as being of similar intensity to the positive control group: P450 1A1, β-naphthoﬂavone; P450 2B1/2, phenobarbitone;
P450 3A1, dexamethasone; P450 4A1, methylclofenapate).Articles • Prediction of rodent nongenotoxic carcinogenesis
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Figure 1. Schematic representation of the group mean results for the parameters given in Table 4 and the carcinogenicity results from the NTP bioassays for the
rat (A) and the mouse (B). Abbreviations: H, high dose; L, low dose; LI, labeling index. Red, clearly positive results; blue, negative results; pink, equivocal result;
white, parameter not determined.(T3) levels by radioimmunoassay using pro-
prietary kits obtained from Amersham
International (Buckinghamshire, UK; TSH)
and Diagnostic Products Corp. (Los Angeles,
CA, USA; T3 and T4). Plasma T3 levels were
not determined in mice because there was
insufﬁcient plasma for all assays.
Kidney. α2u-Globulin distribution was
determined by immunohistochemistry as
described by Stonard et al. (26).
Results
Body weight changes for rats and mice
throughout most of the studies were within
those previously observed in the NTP bioas-
says, and there were no clinical signs of toxi-
city for any of the compounds tested. The
two exceptions to this were MON in the
mouse, where unacceptable toxicity led to
the discontinuation of studies in both males
and females at the high doses (results not
presented), and CINN, where unacceptable
loss of body weight occurred in both species
at the high dose. Food consumption for
high-dose CINN was reduced, indicating
poor palatability. The high dose of CINN
was therefore reduced from 30,000 ppm to
22,000 ppm for both species. 
The parameters listed in Table 4 were
determined as potential predictors of
nongenotoxic carcinogenesis in the liver, thy-
roid gland, and kidney. The criteria used to
define clearly positive results, equivocal
results, and negative results for each organ are
also given. Data were not subjected to statis-
tical analysis. We set the criteria after viewing
the data for the parameters determined and
based the criteria on our experience of inter-
preting changes with these parameters, litera-
ture data where possible (27–29), and the
actual data obtained. We accept that our cri-
teria are arbitary and that other workers may
have chosen to use different criteria (e.g., a
4-fold increase in cell proliferation represent-
ing a positive result rather than the 2-fold
increase we have chosen). A different set of
results may have been obtained using a differ-
ent set of criteria, but the overall trends dis-
cussed are unlikely to have changed.
Numerical results are not presented for the
parameters because of the volume of results.
Instead, positive results, equivocal results,
and negative results are presented in Figure 1
in color-coded schematic ﬁgures of the results
for both species. The carcinogenicity results
of the NTP bioassays are also presented in
Figure 1 for comparison. Some time points
and groups were not analyzed for certain
parameters, for example, in cases where nega-
tive results were obtained for the high doses
of compounds but the low doses were not
analyzed. These are indicated in Figure 1.
The tumor incidences in animals exposed
to DEHP, CINN, CEA, MON, ETU,
DETU, and TMTU for 1 year (in the satel-
lite studies) are shown in Table 5. Where
tumors were observed at this time point, the
results were in accordance with those of the
NTP except for TMTU, which is discussed
below.
Rat
Liver. In the rat, liver weight and liver
hypertrophy were clearly increased by
DEHP, CINN and DCB, as reported by
others (30–32). MON, ETU, and LIM also
gave weak increases in liver weight that
were sometimes accompanied by liver
hypertrophy. Increased liver weight after
LIM administration has been shown previ-
ously (33). DETU, CEA, and TMTU gave
little or no increases in liver weight, but
CEA and TMTU did produce liver hyper-
trophy at later time points. Of the three rat
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Table 5. Carcinogenicity of the chemicals after administration for 1 year as part of the present study.
Test Sex, Rat Mouse
agent dose Liver Thyroid Kidney Liver Thyroid Kidney
DEHP Male
C0 0 0 1 0 0 0
L0 0 0 3 0 0 0
H0 0 0 2 0 0 0
Female
C0 0 0 0 0 0
L0 0 0 1 1 0 0
H0 0 0 2 2 0 0
CINN Male
C0 0 0 1 0 0 0
L0 0 0 4 0 0 0
H0 0 0 1 0 0 0
Female
C0 0 0 0 0 0
L0 0 0 0 0 0
H0 0 0 1 0 0 0
CEA Male
C0 0 0 0 0 0
L0 0 0 1 1 0 0
H0 0 0 1 1 0 0
Female
C0 0 0 0 0 0
L0 0 0 0 0 0
H0 0 0 0 0 0
MON Male
C0 0 0 0 0 0
L0 0 0 1 0 0 0
H0 00Withdrawn
Female
C0 0 0 0 0 0
L0 0 0 0 0 0
H0 00Withdrawn
ETU Male
C0 0 0 0 0 0
L0 0 0 1 7 0 0
H0 9 0 0 7 5 100 0
Female
C0 0 0 0 0 0
L0 0 0 0 0 0
H0 2 0 0 100 86 0
DETU Male
C0 0 0 1 0 0 0
L0 0 0 0 0 0
H0 3 0 0 3 0 0 0
Female
C0 0 0 0 0 0
L0 0 0 0 0 0
H0 1 0 0 2 0 0 0
TMTU Male
C0 0 0
L0 0 0
H0 0 8 0
Female
C0 0 0
L0 3 0 0
H0 100 0
Abbreviations: C, control; H, high dose; L, low dose. Values shown are the percentage of tumor-bearing animals (combined
adenoma and carcinoma incidence). liver carcinogens (DEHP, CEA, and
MON) in this group of chemicals, only the
peroxisome proliferator DEHP showed an
association between liver growth and hepa-
tocarcinogenicity. A better association was
observed between labeling index (at 7, 28,
or 90 days) and hepatocarcinogenicity.
DEHP, CEA, and MON all increased
labeling index, although the time courses
were different. The noncarcinogens CINN,
DCB, ETU, TMTU, and LIM also gave
increases in labeling index; only DETU had
no effect. Increases in labeling index pro-
duced by some of these compounds have
been shown previously (27,30,31,34).
All of the compounds tested gave
increases in cytochrome P450, determined
either as total (spectral) P450 or as specific
isoforms (Western blots). Where the P450
induction proﬁles of compounds have previ-
ously been described (32,35,36), the results
were as expected; for example, the peroxi-
some proliferator DEHP gave clear increases
in total P450 and CYP 4A1 and some weak
increases in CYP 2B1/2. In some cases,
CEA, for example, total P450 was not
increased, but there was weak induction of
CYP 2B1/2 and CYP 3A1. This indicated a
redistribution in the proﬁle of P450s present
in the liver. In other cases, such as ETU,
DETU, and TMTU, the reverse occurred:
total P450 was increased but there were no
changes in the isozymes tested. It is probable
that these chemicals induced a P450 isoform
that was different from those tested.
We observed increases in PCoA with the
peroxisome proliferators DEHP and CINN.
Table 6 shows the quantitative changes in
induction of PCoA. DEHP produced a
much greater increase than CINN in the rat,
correlating with the carcinogenicity of
DEHP and noncarcinogenicity of CINN in
this species. The increases in PCoA after
DEHP and CINN treatment are as described
previously (31,32).
Thyroid gland. In the rat thyroid, weight,
hyperplasia, and hypertrophy were increased
at most dose levels and time points by the
three thyroid carcinogens tested: ETU,
DETU, and TMTU. However, specificity
between low and high doses, and between
sexes within the chemicals was not apparent.
Low-dose DETU in male rats was not car-
cinogenic, and TMTU was only carcinogenic
in high-dose female rats; similar profiles of
effects for these three markers were observed
across both sexes and groups. TMTU, how-
ever, when administered for 1 year, gave a
different profile of thyroid gland tumors
from those seen in the NTP studies, with
increased tumor incidence in high-dose males
and high- and low-dose females (Tables 1, 2,
and 5). The results of all of the short-term
markers correlate better with these results.
ETU, DETU, and TMTU decreased total
T4 after 7 days of treatment. Effects on T4
levels at later time points differed between
these three compounds; for example, TMTU
at both dose levels and sexes decreased T4
after 28 and 90 days, whereas T4 levels were
unaffected in males given both doses of
DETU at 90 days. TSH levels were generally
increased when T4 levels were decreased, in
agreement with the known mechanism of
feedback control in the thyroid (37). The
thyroid labeling index usually paralleled the
increased TSH levels; for example, all groups
with increased TSH at 7 days also had
increased labeling indices. T3 levels were
decreased when T4 levels were decreased, but
changes in this parameter were not as closely
paralleled by TSH and labeling index as T4. 
In the rat, the thyroid noncarcinogens
DEHP and DCB produced clear decreases
in T4 levels in some groups, thyroid hyper-
trophy, and increased thyroid weight. There
were no increases however in TSH levels or
labeling index, although some thyroid
hyperplasia was observed histopathologically.
CINN decreased T4 and T3 levels after 7
days and produced some hypertrophy, indi-
cating a weak effect on the thyroid. These
compounds were also the most potent
inducers of liver growth and P450 isoforms
in the liver. Chemicals that produce these
effects in the liver increase the clearance of
thyroid hormones by increasing hepatic
blood flow. Inducers of CYP 2B1/2 also
induce the glucuronyl transferases responsi-
ble for the metabolism of T4 and T3 and
hence increase their clearance (38). CEA,
MON, and LIM gave some changes in the
parameters tested for the thyroid gland, but
there were no consistent patterns indicative
of effects in the thyroid. 
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Table 6. The effect of DEHP and CINN on PCoA oxidase activity. 
DEHPa CINNa Control valuesb
Species Sex/time Low dose High dose Low dose High dose (nmol/min/mg)
Rat Male
7 day 662 735 227 252 15.2 ± 7.5; 6.2 ± 0.7c
28 day 467 916 218 241 11.8 ± 2.8; 18.6 ± 2.5
90 day 611 1,036 161 187 12.4 ± 2.5; 20.0 ± 2.6
Female
7 day 295 398 206 189 20.3 ± 5.3; 24.0 ± 2.6
28 day 336 531 234 219 12.2 ± 8.0; 20.3 ± 1.7
90 day 395 661 195 253 16.0 ± 2.4; 22.1 ± 1.7
Mouse Male
7 day 211 325 419 513 17.2 ± 6.5
28 day 258 332 426 422 22.9 ± 5.2
90 day 225 249 311 341 17.7 ± 4.1
Female
7 day 300 317 345 459 20.5 ± 3.3
28 day 240 321 360 430 23.9 ± 4.1
90 day 183 206 282 299 25.3 ± 5.2
aValues are expressed as percentage of control values. bActual control values. cThe ﬁrst and second sets of ﬁgures refer
to the control groups from separate rat studies with DEHP and CINN, respectively; in the mouse, studies with DEHP,
CINN, and a common control group were run concurrently.
Figure 2. The relationship between (plasma) total T4 and TSH in (A) the rat and (B) the mouse. Data points represent the group means for control groups and all
nine (rat) or seven (mouse) compounds at both dose levels for all time points and both sexes.
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T4 and TSH by plotting mean TSH versus
T4 levels for untreated and treated male and
female rats for all of the chemicals and at all
of the time points (Figure 2A). This relation-
ship indicates that there is a threshold level of
T4 that must be reached before TSH begins
to increase. In rats of both sexes, this appears
to be approximately 20 nmol/L. Once this
threshold is reached and TSH rises, DNA
synthesis is thought to be stimulated in the
thyroid, although there does not appear to be
a simple quantitative relationship between
TSH and labeling index (data not shown). In
the cases of the thyroid carcinogens ETU,
DETU, and TMTU, levels of T4 decreased
below the threshold of 20 nmol/L; therefore,
the later events of increased TSH and label-
ing index, thyroid hyperplasia, and marked
increases in thyroid weight followed. For the
noncarcinogens affecting thyroid markers,
plasma T4, although decreased, did not fall
below the threshold; therefore, the later
events did not follow.
Kidney. In the rat, dose- and duration-
related increases in kidney weights were pro-
duced by DEHP, CINN, DCB, MON, and
LIM in both male and female animals.
DCB, MON, and LIM are male kidney car-
cinogens, but it was notable that the greatest
effects on kidney weight were produced by
chemicals that also had the greatest effects
on liver weight. The increases in kidney
weight were more marked in males but were
also observed in females. CEA, ETU,
DETU, and TMTU had little or no effect
on kidney weight. The rat kidney carcino-
gens DCB, MON, and LIM increased the
labeling index in male rat kidney, although
the time courses were different (Figure 3).
MON increased the labeling index after 7
days only, whereas DCB and LIM increased
the labeling index after 28 and 90 days.
CINN (also a male rat kidney carcinogen)
had no effect on labeling index in the rat,
but at early time points this may have been
due to decreased body weight gain due to
nonconsumption of diet. Increased hyaline
droplet formation in males was observed at
all time points with DCB and LIM [as
described by Hard et al. (39)], but not with
MON or CINN. Immunohistologic staining
of kidney sections from these groups con-
ﬁrmed that α2u-globulin was increased with
DCB and LIM but not with MON or
CINN (data not shown). Tubular basophilia
was evident to some degree in all groups in
male animals only, although the most
marked changes were seen with CINN,
DCB, and LIM. DCB and LIM were the
only compounds that produced granular
casts at the corticomeullary junction. The
findings with DCB and LIM are in agree-
ment with the known mechanism of action
of these compounds; that is, α2u-globulin
accumulation and the subsequent changes
associated with this (40).
Mouse
Liver. In the mouse liver, weight, labeling
index, and liver hypertrophy were clearly
increased by the hepatocarcinogens DEHP,
CINN, DCB, and ETU. Some of the effects
of DEHP, CINN, and DCB have been
shown previously (30,31,41). CEA, MON,
and DETU gave little or no increases in liver
weight but did produce some hypertrophy,
which was observed microscopically. In this
species, CEA was carcinogenic in males only.
The hepatocarcinogens DEHP, CINN,
DCB, and ETU increased the labeling index
at 7, 28, and 90 days, although CEA failed
to increase the labeling index at any time
point. The liver noncarcinogens MON and
DETU had no effect on labeling indices. 
All the chemicals tested gave increases in
P450, determined either as total (spectral)
P450 or as speciﬁc isoforms (Western blots).
Induction of P450 by DEHP, CINN, and
DCB was in agreement with previous work
(31,42,43). We observed induction of CYP
isoforms without increases in total P450
(CEA), and we also observed increases in
total P450 without induction of the isoforms
tested (ETU, DETU) as in the rat. 
The peroxisome proliferators DEHP and
CINN gave clear increases in PCoA in the
mouse. Both of these hepatocarcinogens are
known to be peroxisome proliferators in
mice (27). Table 6 shows the quantitative
changes in induction of the peroxisomal
marker enzyme PCoA. The increases in this
parameter correlate well with the carcino-
genicity of CINN in mice and to some
extent with DEHP, although here induction
of PCoA was weaker.
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Figure 3. Labeling indices (LI) for NTP kidney carcinogens in male rat kidneys after (A) 7, (B) 28, and (C) 90
days. The colors of the bars represent the classiﬁcation of the results as shown in Figure 1. The dashed
line indicates the threshold for a clearly positive result for LI (≥ 200% of control as deﬁned in Table 4). All
test compounds were carcinogenic to the male rat kidney except for the low dose of CINN. 
250
200
150
100
50
0
300
250
200
150
100
50
0
700
600
500
400
300
200
100
0
Low
dose
High
dose
Low
dose
High
dose
Low
dose
High
dose
Low
dose
High
dose
CINN DCB MON LIM
L
I
 
(
%
 
c
o
n
t
r
o
l
 
v
a
l
u
e
s
)
A
B
C
Low
dose
High
dose
Low
dose
High
dose
Low
dose
High
dose
Low
dose
High
dose
Low
dose
High
dose
Low
dose
High
dose
Low
dose
High
dose
Low
dose
High
dose
L
I
 
(
%
 
c
o
n
t
r
o
l
 
v
a
l
u
e
s
)
L
I
 
(
%
 
c
o
n
t
r
o
l
 
v
a
l
u
e
s
)
Clearly positive
Negative
EquivocalThyroid. In the mouse, ETU was the
only thyroid carcinogen tested. Decreased
T4, increased TSH, labeling index, and thy-
roid hypertrophy and hyperplasia, at all
time points, were consistant with the dose
and sex specificity for carcinogenicity in
low- and high-dose males and high-dose
females. The lack of effect of ETU on TSH
in females given carcinogenic (low) doses
however was not consistent with dose and
sex speciﬁcity. 
The noncarcinogens DETU and MON
in the mouse produced clear decreases in T4
levels, but these were not accompanied by
increases in TSH levels, labeling index, or
histopathologic changes. DEHP, CEA, and
DCB gave occasional small decreases in T4
without affecting TSH levels. The effects of
DEHP and DCB on the thyroid were much
less marked than those observed in the rat.
The only chemical that was completely with-
out effect was CINN.
As in the rat, we investigated the rela-
tionship between T4 and TSH in mice by
plotting mean TSH versus T4 levels for
untreated and treated male and female mice
for all the chemicals and at all the time
points (Figure 2B). The relationship is not as
clear as in the rat, probably because only one
chemical was a thyroid carcinogen.
Nevertheless, Figure 2 indicates that there is
also a threshold level of T4 in the mouse,
which must be reached before TSH starts to
rise. This also appears to be approximately
20 nmol/L. The same relationship between
TSH, DNA synthesis, thyroid hyperplasia,
and marked increases in thyroid weight is
thought to exist in the mouse. As in the rat,
the thyroid carcinogen ETU decreased T4
levels below the threshold of 20 nmol/L and
thus the later events followed. For the non-
carcinogens affecting thyroid markers,
plasma T4, although decreased, did not fall
below the threshold; therefore, the later
events did not follow. 
Kidney. None of the compounds were
kidney carcinogens in the mouse. Increased
kidney weights were observed with CINN,
DCB, and ETU only. These compounds
also produced marked liver growth in the
mouse. CINN also increased the labeling
index. Hyaline droplets, tubular basophilia,
and granular cast formation were not seen in
any mice.
Discussion
The present study was initiated to investigate,
in a systematic way, whether biologic changes
that have previously been associated with
nongenotoxic rodent carcinogenesis could
singly, or in concert, form the basis of a pre-
dictive strategy. To this end, we simulated as
far as possible the conditions of bioassay used
by the NTP while deﬁning the carcinogenic-
ity of nine rodent carcinogens (44). During
the early stages of this simulation, we evalu-
ated a range of acute/subacute markers of
presumed nongenotoxic rodent carcinogene-
sis. The markers used in this study have been
reported by others for the rodent liver
(27,28,30,31,41), kidney (9,26,33,39,40),
and thyroid gland (9,37,38). The results of
the study for individual markers are shown
schematically in Figure 1. The extent to
which the positive carcinogenicity classiﬁca-
tions for the test chemicals are followed by
the respective markers in the tissues sensitive
to carcinogenesis become clear. Before ana-
lyzing the data in detail (according to the
questions posed in Table 3), we will discuss
four general conclusions of the study that
inﬂuence the analysis. 
First, gross inspection of Figure 1 reveals
that the marker results are not random and
that, in general, the acute/subacute tissue
changes monitored are associated with car-
cinogenesis. A speciﬁc example of this is the
good performance of the rat kidney markers
for all of the chemicals tested, an effect
enhanced by the essential totality of negative
marker responses (blue entries in Figure 1) in
the mouse kidney, corresponding to the
absence of mouse kidney carcinogens in this
study. However, a danger faced when analyz-
ing the data in more detail is that the results
may be fragmented to yield perhaps unjusti-
ﬁed species- or chemical-speciﬁc conclusions
regarding the predictive value of individual
markers. Although this may be acceptable
when supported by a mechanistic rationale,
as with the use of enzymes associated with
peroxisome proliferation in predicting perox-
isome proliferator rodent liver carcinogens, it
can be delusory when performed without
such a guiding principle. An example of the
latter would be to conclude that the bank of
positive markers (red entries in Figure 1)
associated with DEHP in the rat liver are
predictive of its rat liver carcinogenicity,
while ignoring the equally large bank of posi-
tive marker results in the rat liver for the rat
liver noncarcinogen CINN. In contrast, both
DEHP and CINN are carcinogenic to the
mouse liver, activities that are supported by
the bank of red liver markers seen for both
chemicals in the mouse (Figure 1). This dan-
ger is particularly relevant to most of the ear-
lier studies in this area in which the
acute/subacute “predictive” tissue responses
of isolated carcinogens were monitored in
isolated species and tissues without the con-
comitant evaluation of negative control
agents. Similar conditional conclusions could
be derived and then challenged for the
responses in the rat to the three thyroid gland
carcinogens ETU, DETU, and TMTU
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Table 7. Prediction of carcinogenicity in the rat or mouse liver by organ-speciﬁc parameters.a
Rat Mouse 
Percent of data sets Percent of data sets
Parameter 7 day 28 day 90 day n 7 day 28 day 90 day n
Relative liver weight
Accuracyb 72 64 58 36 88 88 84 26
Sensitivityc 40 40 40 10 82 82 82 17
Speciﬁcityd 85 73 65 26 100 100 89 9
Labeling index
Accuracy 44 64 67 36 81 38 62 26
Sensitivity 40 10 20 10 71 6 41 17
Speciﬁcity 46 85 85 26 100 100 100 9
Liver hypertrophy
Accuracy 64 64 56 36 69 92 69 26
Sensitivity 40 60 60 10 65 94 65 17
Speciﬁcity 73 65 54 26 78 89 78 9
PCoA oxidase induction
Accuracy ND  ND 82 22 ND ND 50 18
Sensitivity 57 7 31 13
Speciﬁcity 93 15 100 5
Total P450 induction
Accuracy 28 33 50 18 72 50 64 14
Sensitivity 20 20 20 5 14 21 78 9
Speciﬁcity 31 38 62 13 14 29 40 5
P450 isoform inductione
Accuracy ND  ND 61 18 ND ND 64 14
Sensitivity 40 5 44 9
Speciﬁcity 69 13 100 5
Abbreviations: n, number of total number of data sets; ND, not determined.
aPrediction of carcinogenicity in the rat and mouse was assessed by counting numbers of data sets shown in Figure 1; a
data set was deﬁned as the carcinogenicity result (C) and parameter (P) results for a speciﬁc compound, species, sex,
dose, and time point (e.g., one data set includes the carcinogenicity result and the liver weight result for male rats given
low-dose DEHP). bThe correct identiﬁcation of carcinogenic activity for all chemicals (50) (i.e., Figure 1, C blue, P blue
and C red, P red). cThe proportion of carcinogenic responses correctly identiﬁed for carcinogenic chemicals only (45)
(i.e., Figure 1, C red, P red). dThe proportion of noncarcinogenic responses correctly identified for noncarcinogenic
chemicals only (45) (i.e., Figure 1, C blue, P blue); equivocal results (Figure 1, pink) were taken to be negative for this
analysis. eA positive result for any of the isoforms was taken as a positive for this parameter.(Figure 1). The first overall conclusion is
therefore that the predictive value of individ-
ual markers can sometimes be seminally
modulated by focusing either on carcinogens
and species in general, or on speciﬁc carcino-
gens in speciﬁc species. 
The second general conclusion derives
from consideration of the counterproposal,
namely, that positive marker changes seen
for a chemical classified as noncarcinogenic
to a particular tissue indicate the presence of
a carcinogenic potential for the agent in that
tissue which was not realized during the
course of the NTP carcinogenicity bioassay.
Some credence for this possibility is afforded
by the data available for TMTU. This com-
pound was classified by the NTP as being
carcinogenic only in the thyroid gland of
female rats, and then only at the high dose
(Tables 1 and 2). In the present study, the
majority of the marker events in the rat thy-
roid gland gave positive results for TMTU,
irrespective of the dose studied and the sex
of rat evaluated (Figure 1). This would indi-
cate that the thyroid gland markers studied
were not specific for the carcinogenicity of
TMTU, despite being predictive of the thy-
roid gland carcinogenicity of the high dose
of TMTU to the female rat. However, in the
satellite study in which rats were exposed to
TMTU for 1 year, it was found that TMTU
was carcinogenic to both high- and low-dose
female rats and to high-dose male rats. This
carcinogenic proﬁle correlates well with the
marker changes observed at the earlier time
points (Figure 1). Obviously, the NTP car-
cinogenicity data must be maintained as the
primary calibrant for this study, but the data
derived here for TMTU suggests that the
carcinogenic profile of a chemical is not
absolute (4–7,45) and that, in fact, tissue
changes seen for some chemicals classiﬁed as
noncarcinogenic may be predicative of an as
yet unrealized, or perhaps ultimately unreal-
izable, carcinogenic activity.
The third general conclusion relates to
the second, and concerns the possibility that
some tissue markers may be indicative of tis-
sue changes necessary for carcinogenesis, but
are insufﬁcient for it when they occur alone.
This would reduce the value of the markers
but not render them useless. This possibility
is illustrated by the changes in thyroid hor-
mones observed (Figure 2) for the thyroid
gland carcinogens ETU, DETU, and
TMTU (Tables 1 and 2, Figure 1). From
these data (Figure 2) it is clear that reduction
of total T4 levels to about 20 nmol/L are
required before increases in TSH are
observed, the latter being considered to be
the event most predicative of the induction
of thyroid gland hyperplasia and eventual
carcinogenesis (37). A cascade is therefore
indicated by these data in which reductions
in T4 levels can be seen as contributing to
the carcinogenic process, but being nonspe-
ciﬁc for it until the reduction is sufﬁcient to
trigger an elevation in TSH levels. This con-
cept severely complicates analysis of the
database because markers may be prema-
turely neglected due to their failure to corre-
late fully with carcinogenesis in the affected
tissue. Equally, some markers may be totally
independent of the carcinogenic process, as
probably indicated by the cytochrome P450
changes seen here in the rodent liver.
Resolving these two possibilities requires
judgment, itself open to preconception and
unintentional bias.
The ﬁnal general conclusion relates to the
proposed validity of our decision to apply
qualitative positive test criteria to our data, as
opposed to conducting statistical analyses of
the data. This decision is the same as that
adopted by pathologists when assessing a tis-
sue for chemically induced changes: the terms
minimal, mild, moderate, severe being uni-
versally owned for this purpose (46).
Similarly, the original NTP low-dose carcino-
genicity bioassay results were concluded quali-
tatively for the present study by Joseph
Haseman of the NTP (Table 2). The qualita-
tive test outcome criteria used here were based
on our experience with the end points beyond
this study (Table 4), in particular, knowledge
of the magnitude of changes that could be
considered beyond experimental variability
and therefore likely to be chemically induced.
The practice of these criteria is exempliﬁed in
Figure 3 for the four rat kidney carcinogens
evaluated. Rigorous statistical analyses of
those test data (Figure 3) may have influ-
enced, challenged, or reﬁned close calls such
as the 7-day equivocal result for the high dose
of LIM and the 7-day positive result for the
high dose of MON. However, we concluded
that the general sweep of the test results
(Figure 1) would not have been substantially
changed by statistical analyses, and it may
even have been confused by positive statistical
conclusions that failed to carry practical credi-
bility. As noted earlier, the primary test data
from this study will be made available to
interested parties for statistical analysis. 
Liver. The overall accuracy figures for
the liver markers considered are shown in
Table 7. The only high accuracy ﬁgures are
for increases in the relative weight of mouse
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Table 8. Prediction of carcinogenicity in the rat or mouse thyroid gland by organ-speciﬁc parameters.a
Rat Mouse 
Percent of data sets Percent of data sets
Parameter 7 day 28 day 90 day n 7 day 28 day 90 day n
Relative thyroid weight
Accuracyb 86 81 69 36 ND ND ND
Sensitivityc 88 75 75 8
Speciﬁcityd 86 82 68 28
Labeling index
Accuracy 89 81 78 36 100 96 96 26
Sensitivity 100 75 13 8 100 100 100 3
Speciﬁcity 86 82 96 28 100 96 96 23
Thyroid hypertrophy
Accuracy 78 78 78 36 96 96 96 26
Sensitivity 75 88 100 8 67 100 100 3
Speciﬁcity 82 75 71 28 28 100 96 23
Thyroid hyperplasia 
Accuracy 81  83 86 36 92 96 100 26
Sensitivity 75 88 100 8 33 100 100 3
Speciﬁcity 79 82 82 28 100 96 100 23
Total T3
Accuracy 62 63 67 24 ND ND ND
Sensitivity 50 13 13 8
Speciﬁcity 69 88 94 16
Total T4
Accuracy 79  63 66 24 72 78 78 18
Sensitivity 100 88 75 8 100 100 100 3
Speciﬁcity 69 56 63 16 67 73 73 15
TSH 
Accuracy 83  75 67 24 94 94 94 18
Sensitivity 88 63 25 8 67 67 67 3
Speciﬁcity 81 81 88 16 100 100 100 15
Abbreviations: n, number of total number of data sets; ND, not determined.
aPrediction of carcinogenicity in the rat and mouse was assessed by counting numbers of data sets shown in Figure 1; a
data set was deﬁned as the carcinogenicity result (C) and parameter (P) results for a speciﬁc compound, species, sex,
dose, and time point (e.g., one data set includes the carcinogenicity result and the liver weight result for male rats given
low-dose DEHP). bThe correct identiﬁcation of carcinogenic activity for all chemicals (50) (i.e., Figure 1, C blue, P blue
and C red, P red). cThe proportion of carcinogenic responses correctly identiﬁed for carcinogenic chemicals only (45)
(i.e., Figure 1, C red, P red). dThe proportion of noncarcinogenic responses correctly identified for noncarcinogenic
chemicals only (45) (i.e., Figure 1, C blue, P blue); equivocal results (Figure 1, pink) were taken to be negative for this
analysis. eA positive result for any of the isoforms was taken as a positive for this parameter. liver following chemical treatment (≥ 84%
accuracy). Overall, none of the markers cor-
relate well with rat liver carcinogenicity,
albeit the mouse ﬁgures are marginally bet-
ter. Cytochrome P450 (total and isoen-
zymes) induction generally correlated poorly
with carcinogenicity. The PCoA and the
P450 4A1 induction data are somewhat arti-
ficial, given that these are specific enzymes
associated with peroxisome proliferation,
and only one rat and two mouse peroxisome
proliferator liver carcinogens were included
in the study (DEHP and CINN; Table 6).
Nonetheless, the induction of these two
enzymes was highly specific for these two
chemicals in both rat and the mouse liver
(enzyme induction was only determined for
the high dose groups for the remaining seven
chemicals). Overall, the best general markers
of rodent liver cancer are increases in relative
liver weight and cellular labeling index (par-
ticularly for the mouse) and liver hypertro-
phy. There was no optimum time for the
measurement of these changes, albeit the early
time point (7 days) was generally the best.
Thyroid gland. With the exception of T3
and T4 levels, all of the markers studied cor-
related well with thyroid gland carcinogenic-
ity (Table 8). The low accuracy values for
decreases in the levels of T3 and T4 are prob-
ably associated with the need to exceed a
threshold reduction before increases in TSH
are produced (see above and Figure 2). The
accuracy of all of the markers would have
been increased if TMTU had been classiﬁed
as a carcinogen in male rats (high dose) and
female rats (low and high doses) instead of
just for the high-dose female rats (as in the
NTP study; see above and Table 5).
Kidney. Because no mouse renal carcino-
gens were included in this study, the bank of
blue (negative results) for the mouse kidney
markers (Figure 1) acts as an indicator of the
high specificity of the positive marker
responses seen for the four rat renal carcino-
gens evaluated (CINN, DCB, MON, and
LIM; Table 9). As expected from earlier
studies, increases in cell labeling indices
(especially at the later sampling times) and
hyaline droplet formation (particularly at the
earlier sampling times) acted as good predic-
tors of the carcinogenicity of DCB and LIM.
These changes, which were specific to the
affected male animals, are consistent with
the α2u-globulin mechanism of male rat
renal cancer induction. The absence of
increases in kidney weight for animals
exposed to LIM (and MON) is in contrast
to the increases seen for animals exposed to
DCB (and CINN), but there is no obvious
explanation for these differences. The car-
cinogenicity of the remaining two rat renal
carcinogens (CINN and MON) was poorly
predicted by the markers evaluated. Relative
kidney-weight increases for CINN were not
specific to the affected males, and no such
changes were induced by MON. Similarly,
renal tubular basophilia was specific to the
affected male rat in the case of CINN but
was not seen for animals exposed to MON.
Time of measurement. We observed that
increases in relative tissue weight, indepen-
dent of the carcinogenicity of the agent to
that tissue, occurred from the earliest (7
days) to the latest times monitored here (90
days). With few exceptions (e.g., MON in
the rat thyroid and DCB and LIM in the rat
liver), increases in labeling index for all three
tissues are most evident at the 7-day sam-
pling period. Liver hypertrophy either occurs
at all three sampling times or sporadically
across the chemical test groups at the later
two sampling times. There is no obvious
correlation between these two patterns and
rat liver carcinogenicity. Thyroid gland
hypertrophy and hyperplasia correlate well at
all time points with carcinogenicity, except in
the case of DEHP in the rat. Among the liver
enzyme induction effects seen, only those for
PCoA and P450 4A1 (enzymes associated
with peroxisome proliferation) correlated
usefully with carcinogenicity, and then only
when the two peroxisome proliferator car-
cinogens were considered. In these cases the
changes were apparent at all of the sampling
times evaluated. Increases in TSH correlated
well with thyroid gland carcinogenicity, and
these increases were evident primarily at the
earlier sampling times. Decreases in total T3
and T4 were less speciﬁc for carcinogenicity
and also occurred primarily at the earlier sam-
pling times. The time course of changes in the
rat kidney is in accordance with the mecha-
nism of α2u-globulin-induced nephropathy
in which hyaline droplet formation is the ear-
liest event, followed by tubular basophilia,
and then granular casts, which were an
“equivocal” finding with DCB and LIM in
this study.
The importance of cell proliferation and
apoptosis. There is some controversy over the
merit of determining transient increases in
cell proliferation (as determined in this study)
versus sustained increases, the latter of which
have been suggested by some to be necessary
to drive carcinogenesis. It is well known from
initiation–promotion studies in which ani-
mals are treated with a mutagen and a subse-
quent regimen that induces cell proliferation
that the relatively transient induction of cell
replication associated with these procedures
effectively promotes an already mutated pop-
ulation of cells to affect an enhanced number
of tumors, or shortens the latency for tumor
appearance (47). It is also apparent that the
more rounds of replication that occur, as in
sustained cytotoxin-induced cell replication,
the more chances there are of inducing muta-
tions in a previously nonmutated cell popula-
tion or of inducing additional mutations in
the population. Therefore, although it is clear
that sustained cell replication carries an
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Table 9. Prediction of carcinogenicity in the rat or mouse kidney by organ-speciﬁc parameters.a
Rat Mouse 
Percent of data sets Percent of data sets
Parameter 7 day 28 day 90 day n 7 day 28 day 90 day n
Relative kidney weight
Accuracyb 86 78 81 36 96 92 92 26
Sensitivityc 43 29 43 7 – – – 0
Speciﬁcityd 97 90 83 29 96 92 92 26
Labeling index
Accuracy 83 92 92 36 100 100 92 26
Sensitivity 14 57 57 7 – – – 0
Speciﬁcity 100 100 100 29 100 100 92 26
Hyaline droplet formation
Accuracy 89 89 86 36 36 100 100 26
Sensitivity 43 43 29 7 – – – 0
Speciﬁcity 100 100 100 29 100 100 100 26
Tubular basophilia
Accuracy 81  86 89 36 100 100 100 26
Sensitivity 0 43 43 7 – – – 0
Speciﬁcity 100 97 100 29 100 100 100 26
Granular cast formation 
Accuracy 81 81 81 36 100 100 100 26
Sensitivity 0 0 0 7 – – – 0
Speciﬁcity 100 100 100 29 100 100 100 26
n, number of total number of data sets.
aPrediction of carcinogenicity in the rat and mouse was assessed by counting numbers of data sets shown in Figure 1; a
data set was deﬁned as the carcinogenicity result (C) and parameter (P) results for a speciﬁc compound, species, sex,
dose, and time point (e.g., one data set includes the carcinogenicity result and the liver weight result for male rats given
low-dose DEHP). bThe correct identiﬁcation of carcinogenic activity for all chemicals (50) (i.e., Figure 1, C blue, P blue
and C red, P red). cThe proportion of carcinogenic responses correctly identiﬁed for carcinogenic chemicals only (45)
(i.e., Figure 1, C red, P red). dThe proportion of noncarcinogenic responses correctly identified for noncarcinogenic
chemicals only (45) (i.e., Figure 1, C blue, P blue); equivocal results (Figure 1, pink) were taken to be negative for this
analysis. eA positive result for any of the isoforms was taken as a positive for this parameter.enhanced risk of developing cancer in the tar-
get tissue, an acute wave of replication, as can
be seen with DEHP in the studies of Marsman
et al. (48), is also associated with a carcinogenic
response in the target tissue, the liver. Also, ele-
vated rates of cell replication are not always
associated with a carcinogenic response in the
affected tissue (49). An interesting case is pro-
vided by chloroform. This chemical induced
regenerative cell replication in the liver and
kidney of B6C3F1 and BDF1 mice, but the
patterns of tumor response were very different
between the two strains and were reﬂective of
differing cytotoxicity as well as the genetic
backgrounds and target organ and sex sensitivi-
ties (49). Thus, cell replication data can pro-
vide a useful aid to the prediction of
nongenotoxic carcinogens, but such data must
be used with care. We did not determine the
rates of apoptosis in addition to cell prolifera-
tion because of the logistics of the current
experimental design. However, assessment of
apoptotic cell rates for those systems in which
correlations between cell replication and cancer
did not exist would be a rational way to test
hypotheses regarding the effect of enhanced
apoptosis on cancer outcome.
Conclusions
There is no single acute or subacute mea-
surement that will alert specifically to the
eventual appearance of chemically induced
tumors of the rodent liver, thyroid gland, or
kidney. The carcinogenic status of a chemi-
cal can therefore only be determined by ref-
erence to lifetime carcinogenicity bioassay
data (2,44). Even so, it must be noted that
the carcinogenic status of a chemical is not
itself an absolute entity, as seen for TMTU
in the present study in comparison to the
NTP bioassay, and as noted for a range of
other chemicals evaluated in accelerated
transgenic rodent bioassays (5–7,45).
However, in the majority of cases, the chem-
ical induction of cancer in a tissue is pre-
ceded by a range of biochemical and
morphologic changes, most of which are
moderately specific for carcinogenicity and
some of which are highly specific for it.
Examples of the latter are provided by
increases in TSH in the thyroid gland, the
induction of hyaline droplets in the rat kid-
ney, and increases in relative liver weight in
the mouse. The only measurements that
failed to correlate usefully with carcinogenic-
ity were the induction of liver enzymes (with
the exception of the enzymes associated with
peroxisome proliferation: P450 4A1 and
PCoA). The majority of the useful markers
are evident at the early times studied (7 and
28 days), but we identified no overall best
time for all markers. Therefore, we con-
cluded that the judicious choice of markers
and evaluation times can aid the detection of
potential nongenotoxic rodent carcinogens.
To a large extent the choices made will be
influenced by the class of chemical under
study, which is prescribed in some situations
(analogue development), but not in others
(routine screening).
One of the more interesting findings of
this study is the lack of alerts to the carcino-
genicity of CEA in the liver of male and
female rats and female mice. Marked increases
in both liver carcinomas and liver adenomas
were seen in all three of these test groups.
Although there were some late-occurring
increases in hypertrophy and labeling index in
the rat liver and late-occurring liver hypertro-
phy in the mouse liver, these effects were not
speciﬁc for carcinogenicity across the four test
groups (male and female rats and mice).
Finally, the greatest strength of the pre-
sent study is the ability to monitor changes
occurring in tissues not subject to carcinogen-
esis by the test agents studied. This ability
enabled severe qualiﬁcations to be applied to
some of the markers that would have
appeared to correlate well with carcinogenic-
ity if only carcinogens for the tissues evaluated
had been studied. For example, the success of
liver weight changes, labeling index, and liver
hypertrophy in the “prediction” of the rat
liver carcinogenicity of DEHP has to be
qualiﬁed once similar responses are seen for
the rat liver noncarcinogen CINN (Figure 1).
This further endorses the need for the ade-
quate study of negative control agents in
assay-validation studies.
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